Septerna (SEPN) Competitors $6.29 +0.22 (+3.62%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$6.38 +0.09 (+1.51%) As of 04/15/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock SEPN vs. SNDX, WVE, COLL, ELVN, DYN, GPCR, ETNB, CMRX, CDMO, and MLYSShould you be buying Septerna stock or one of its competitors? The main competitors of Septerna include Syndax Pharmaceuticals (SNDX), Wave Life Sciences (WVE), Collegium Pharmaceutical (COLL), Enliven Therapeutics (ELVN), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), 89bio (ETNB), Chimerix (CMRX), Avid Bioservices (CDMO), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Septerna vs. Syndax Pharmaceuticals Wave Life Sciences Collegium Pharmaceutical Enliven Therapeutics Dyne Therapeutics Structure Therapeutics 89bio Chimerix Avid Bioservices Mineralys Therapeutics Syndax Pharmaceuticals (NASDAQ:SNDX) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking. Does the media favor SNDX or SEPN? In the previous week, Syndax Pharmaceuticals had 6 more articles in the media than Septerna. MarketBeat recorded 7 mentions for Syndax Pharmaceuticals and 1 mentions for Septerna. Septerna's average media sentiment score of 1.89 beat Syndax Pharmaceuticals' score of 1.01 indicating that Septerna is being referred to more favorably in the news media. Company Overall Sentiment Syndax Pharmaceuticals Positive Septerna Very Positive Is SNDX or SEPN more profitable? Septerna's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syndax PharmaceuticalsN/A -64.34% -57.72% Septerna N/A N/A N/A Do analysts prefer SNDX or SEPN? Syndax Pharmaceuticals currently has a consensus target price of $36.20, suggesting a potential upside of 219.51%. Septerna has a consensus target price of $33.00, suggesting a potential upside of 424.64%. Given Septerna's higher possible upside, analysts plainly believe Septerna is more favorable than Syndax Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Septerna 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community prefer SNDX or SEPN? Syndax Pharmaceuticals received 386 more outperform votes than Septerna when rated by MarketBeat users. However, 71.43% of users gave Septerna an outperform vote while only 65.38% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSyndax PharmaceuticalsOutperform Votes39165.38% Underperform Votes20734.62% SepternaOutperform Votes571.43% Underperform Votes228.57% Which has higher earnings and valuation, SNDX or SEPN? Septerna has lower revenue, but higher earnings than Syndax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyndax Pharmaceuticals$23.68M41.17-$209.36M-$3.73-3.04Septerna$1.08M260.04N/AN/AN/A SummarySepterna beats Syndax Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Remove Ads Get Septerna News Delivered to You Automatically Sign up to receive the latest news and ratings for SEPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEPN vs. The Competition Export to ExcelMetricSepternaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$279.54M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.33%P/E RatioN/A6.7921.7317.81Price / Sales260.04225.93379.1494.58Price / CashN/A65.6738.1534.64Price / BookN/A5.866.464.00Net IncomeN/A$141.86M$3.20B$247.23M7 Day Performance25.30%8.98%6.54%7.26%1 Month Performance-0.16%-12.65%-8.55%-6.26%1 Year PerformanceN/A-11.99%10.33%-0.18% Septerna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEPNSepterna2.0837 of 5 stars$6.29+3.6%$33.00+424.6%N/A$279.54M$1.08M0.00N/APositive NewsSNDXSyndax Pharmaceuticals3.3478 of 5 stars$11.01-2.1%$36.20+228.8%-47.6%$947.34M$23.68M-3.03110Gap DownWVEWave Life Sciences4.1709 of 5 stars$5.80-3.8%$22.60+289.7%+9.4%$890.22M$108.30M-5.23240Short Interest ↑Analyst RevisionCOLLCollegium Pharmaceutical4.0797 of 5 stars$27.38-2.7%$43.60+59.2%-22.8%$879.77M$631.45M11.80210Positive NewsGap DownELVNEnliven Therapeutics2.5632 of 5 stars$17.87-4.4%$38.75+116.8%-14.5%$875.70MN/A-9.4150News CoverageDYNDyne Therapeutics3.5747 of 5 stars$7.49-9.5%$47.46+533.7%-69.1%$847.28MN/A-2.10100GPCRStructure Therapeutics2.5757 of 5 stars$14.31-5.4%$81.29+468.0%-49.8%$820.58MN/A-19.34136News CoverageETNB89bio2.5885 of 5 stars$5.49-4.9%$27.56+401.9%-36.2%$801.45MN/A-1.8940Short Interest ↑News CoverageHigh Trading VolumeCMRXChimerix2.9082 of 5 stars$8.52-0.1%$8.53+0.2%+834.8%$800.15M$212,000.00-9.0690CDMOAvid Bioservices0.7966 of 5 stars$12.50+0.1%$12.25-2.0%+83.8%$799.18M$139.91M-5.23320High Trading VolumeMLYSMineralys Therapeutics2.3958 of 5 stars$12.05-2.8%$33.00+173.9%+12.5%$778.53MN/A-3.3128Insider TradeShort Interest ↑Gap UpHigh Trading Volume Remove Ads Related Companies and Tools Related Companies SNDX Competitors WVE Competitors COLL Competitors ELVN Competitors DYN Competitors GPCR Competitors ETNB Competitors CMRX Competitors CDMO Competitors MLYS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SEPN) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Septerna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Septerna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SEPN Stock Free SEPN Stock Alerts